GE HealthCare Technologies Inc.
GEHC Healthcare Medical Devices
GE HealthCare Technologies Inc.’s revenue for fiscal 2025 (year ended December 2025) was $20.6 billion, up 4.84% from fiscal 2024. In the quarter to June 2026, revenue grew 5.75%, EPS grew 17.0%, free cash flow grew 750.0% and total debt was flat, each against the same quarter a year earlier. Member of the S&P 500 and Nasdaq 100; dividend growth for three consecutive years, revenue growth for five; insiders bought in the last twelve months.
Follow GEHC
GE HealthCare Technologies Inc. (GEHC) Return on equity
GE HealthCare Technologies Inc.'s return on equity over the twelve months to 30 June 2026 was 19.2%, down 3.0 percentage points from fiscal 2025 (22.1%). Over the past ten years it has ranged from 0.00% (fiscal 2020) to 25.5% (fiscal 2024); the current reading is higher than 86% of that period. That is above the Medical Devices industry median of −15.3% and above the Healthcare sector median of −31.3%.
Return on equity, annual
Embed this chart
Annual newest first
| Period | Return on equity | Change (points) |
|---|---|---|
| FY2025 | 22.1% | (3.43) |
| FY2024 | 25.5% | 8.76 |
| FY2023 | 16.8% | 2.06 |
| FY2022 | 14.7% | 0.42 |
| FY2021 | 14.3% | 14.30 |
| FY2020 | 0.00% | 0.00 |
| FY2019 | 0.00% | — |
Against its own ten years
Return on equity against peers
| Company | Return on equity |
|---|---|
| DXCM DexCom, Inc. compare | 38.5% |
| GEHC GE HealthCare Technologies Inc. | 19.2% |
| BSX Boston Scientific Corporation compare | 15.4% |
| PEN Penumbra, Inc. compare | 11.4% |
| STE STERIS plc compare | 11.4% |
| PHG Koninklijke Philips N.V. compare | 10.2% |
| EW Edwards Lifesciences Corporation compare | 9.42% |
| ZBH Zimmer Biomet Holdings, Inc. compare | 6.41% |
| SNN Smith & Nephew SNATS, Inc. compare | 0.00% |
| Medical Devices industry median | −15.3% |
| Healthcare sector median | −31.3% |
| Market median | 1.35% |
What Return on equity is
ROE shows how much profit a company earns for its shareholders on the equity they have in the business.
Annual: Net Income Allotted to Shareholders ÷ Average Common Equity; TTM: Net Income Allotted to Shareholders ÷ Average Common Equity (latest quarter)
More on GEHC
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement